The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective

References

• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/ ​ ​
   Google Scholar
• Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–3127.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Chronic Myelogenous Leukemia - NCCN Evidence Blocks (Version 1.2016). 2016. ​
   Google Scholar
• Simoneau C-A. Treating Chronic Myeloid Leukemia. Clin J Oncol Nurs. 2013;17:1.
   Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon F-X, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553–561.
   PubMedGoogle Scholar
• Padula WV, Larson RA, Dusetzina SB, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for Chronic Myeloid Leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7):djw003.
   PubMedGoogle Scholar
• Bloudek LM, Makenbaeva D, Eaddy M. Anticipated impact of generic imatinib market entry on the costs of tyrosine kinase inhibitors. Am Health Drug Benefits. 2015;8(9):472.
   PubMedGoogle Scholar
• McDougall J, Ramsey SD, Radich J. What happens when imatinib goes generic? J Natl Compr Cancer Netw. 2016;14(2):128–131.
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789–799.
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst. 1998;90(11):850–858.
   PubMedGoogle Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686–692.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Care Network.  Chronic Myeloid Leukemia (Version 1.2017). 2016. ​
   Google Scholar
• O'Brien, S, Berman, E, Moore J, et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Cancer Netw. 2011;9(Suppl 2):S-1-S-25. ​
   Google Scholar
• Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–2259.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–2270.
   PubMed Web of Science ®Google Scholar
• Höglund M, Sandin F, Hellström K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122(7):1284–1292.
   PubMed Web of Science ®Google Scholar
• Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29(5):1123–1132.
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Gugliotta G, Breccia M, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29(9):1823–1831.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Smith H, Banushi B, et al. Personalized daily doses of Imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with chronic Myeloid leukemia. Final results of the randomized OPTIM Imatinib study. Blood. 2015;126(23):133–133.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive Chronic Myeloid Leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494–500.
   PubMed Web of Science ®Google Scholar
• Branford S, Kim D-W, Soverini S, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012;30(35):4323–4329.
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Müller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096–2102.
   PubMed Web of Science ®Google Scholar
• Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232–238.
   PubMed Web of Science ®Google Scholar
• SCCA. Bone Marrow Transplant for Chronic Myeloid Leukemia. Accessed on 10/17/2016; Available from: https://www.seattlecca.org/diseases/chronic-myeloid-leukemia-cml/treatment-options/bone-marrow-transplant.
   Google Scholar
• Majhail NS, Mau LW, Denzen EM, et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013;48(2):294–300.
   PubMed Web of Science ®Google Scholar
• Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012;120(8):1545–1551.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Lin J, Siegartel LR, et al. # 3573 evaluation of healthcare resource utilization and costs among patients with Chronic Myeloid Leukemia after disease progression, in 58th ASH annual meeting and exposition 2016.San Diego, CA: American Society of Hematology; 2016 Dec 3-6. ​
   Google Scholar
• Sacha T,  Gora-Tybor J, Szarejko M, et al. Imatinib generics in treatment of Chronic Myeloid Leukemia; A prospective observation in Large Cohort of Patients from Polish (PALG) Imatinib Generics Registry. Am Soc Hematology. 2016;128:629 ​ ​
   Google Scholar
• Analy$ource Online, in FDB MedKnowledge (formerly known as NDDF Plus). Data included with permission and copyrighted by First Databank Inc.; 2016. ​
   Google Scholar
• Henk HJ, Woloj M, Shapiro M, et al. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the united states. Clin Ther. 2015;37(1):124–133.
   PubMed Web of Science ®Google Scholar
• Rashid N, Koh HA, Lin K, et al Real world treatment patterns in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors in first line in an integrated healthcare system. Blood. 2015;126(23):5157–5157. ​
   Web of Science ®Google Scholar
• AvalereHealth. Patient out-of-pocket costs for biosimilars in medicare part D. Avalere Health; 2016. ​
   Google Scholar
• Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR‐ABL inhibitors: data from the FDA Adverse Event Reporting System. Am J Hematol. 2015;90(4):E66–E72.
   Google Scholar
• Hochhaus A, Rosti G, Cross NCP, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30(1):57–64.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 2015;6(32):33944–33951.
   PubMed Web of Science ®Google Scholar
• Franklin M, Burns L, Perez S, et al. Incidence of type II diabetes mellitus among patients with Chronic Myelogenous Leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib. J Clin Oncol. 2016;34(suppl):abstr e18126. ​
   Google Scholar
• Franklin M, Burns L, Perez S, et al. Incidence of hyperlipidemia among patients with Chronic Myelogenous Leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib. J Clin Oncol. 2016;34(suppl):abstr e18108. ​
   Google Scholar
• Jabbour E, Makenbaeva D, Lingohr-Smith M, et al. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of Chronic Myelogenous Leukemia based on national comprehensive network treatment guidelines. Clin Lymphoma Myeloma Leuk. 2015;15(12):797–802.
   PubMed Web of Science ®Google Scholar
• D'Souza AO, Makenbaeva D, Farrelly E, et al. Evaluation of cardiovascular disease risk in Chronic Myelogenous Leukemia patients using electronic medical records from community-based oncology practices in the United States. Orlando, FL: in 57th ASH Annual Meeting and Exposition; 2015. ​
   Google Scholar
• D'Souza AO, Makenbaeva D, Farrelly E, et al. Influence of US stroke belt residence on cardiovascular disease risk in Chronic Myelogenous Leukemia, NCCN 2016 2016. ​
   Google Scholar
• Jabbour E, Makenbaeva D, Lingohr-Smith M, et al. Impact of genetic mutations and health plan access to therapies on treatment response and drug costs related to tyrosine kinase inhibitor treatment among patients with Chronic Myelogenous Leukemia. Am J Clin Oncol. 2015;1. ​
   Google Scholar
• Lin J, Makenbaeva D, Bilmes R, et al. Do adverse events related to tyrosine kinase inhibitor treatment among patients with Chronic Myelogenous Leukemia represent a healthcare cost burden in the real-world setting? in NCCN Annual Conference. 2016. ​
   Google Scholar
• Institute, P.B.M. 2014-2015 Prescription Drug Benefit Cost and Plan Design Report. Plano, TX: Pharmacy Benefit Management Institute; 2014.
   Google Scholar
• Kenney JT Jr. Payers’ management of oncology drugs: opportunities and challenges. Am Health Drug Benefits. 2014;7(3):123–124.
   PubMedGoogle Scholar
• Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17(2):143–155.
   PubMed Web of Science ®Google Scholar
• Puig-Junoy J, Moreno-Torres I. Impact of pharmaceutical prior authorisation policies: a systematic review of the literature. Pharmacoeconomics. 2007;25(8):637–648.
   PubMed Web of Science ®Google Scholar
• Holtorf AP, McAdam-Marx C, Schaaf D, et al. Systematic review on quality control for drug management programs: is quality reported in the literature? BMC Health Serv Res. 2009;9:38.
   PubMed Web of Science ®Google Scholar
• Park, J., et al., Impact of managed care restrictions on medication adherence, clinical and economic outcomes, healthcare resource utilization, and treatment satisfaction: A systematic literature review, in Academy of Managed Care Pharmacy Annual Meeting (AMCP). 2016: San Francisco, CA. ​
   Google Scholar
• Carlton RI, Bramley TJ, Nightengale B, et al. Review of outcomes associated with formulary restrictions: focus on step therapy. Am J Pharm Benefits. 2010;2(1):50–58. ​
   Google Scholar
• Happe LE, Clark D, Holliday E, et al. A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Spec Pharm. 2014;20(7):677–684.
   PubMed Web of Science ®Google Scholar
• Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, et al. Health care resource utilization and costs in patients with Chronic Myeloid Leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency. J Manag Care Spec Pharm. 2017;23(2):214–224.
   PubMed Web of Science ®Google Scholar
• Regueiro MD, McAnallen SE, Gree JB, et al. The inflammatory Bowel Disease Specialty Medical Home: A New model of Patient Centered Care. Inflamm Bwel Dis. 2016 Aug; 22(8):1971–1980. doi:10.1097/MIB.0000000000000819.
   Google Scholar